PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study

Xinxing Du(Shanghai Jiao Tong University), Wei Xue(National Sun Yat-sen University), Jia-Zhou Liu(Shanghai Jiao Tong University), Binbin Xia(Shanghai Jiao Tong University), Hanjing Zhu(Shanghai Jiao Tong University), Liang Dong(Chinese PLA General Hospital), Yanqing Wang(Shanghai Jiao Tong University), Xiao-Chen Fei(Shanghai Jiao Tong University), Fan Wu(Fujian Medical University), Jiayi Wang(Dalian University of Technology), Liancheng Fan(Shanghai Jiao Tong University), Yiming Gong(Chongqing University), Yinjie Zhu(Shanghai Jiao Tong University), Baijun Dong(Renji Hospital), Yan-Hao Dong(Shanghai Jiao Tong University), Jiahua Pan(University of Science and Technology of China)
Asian Journal of Andrology
December 13, 2022
Cited by 5


Related Papers